Delivery matters when oral absorption is the concern.
Compounded glutathione nasal spray for a no-needle route designed to fit more naturally into the treatment routine.
About 10 minutes. No charge unless your clinician approves.
Same endogenous molecule. A very different routine.
Glutathione is a three-amino-acid molecule your own cells make and use in normal antioxidant defense. Its biology is not exotic. The format is the distinction.
This preparation is delivered as a nasal spray rather than an injection.
The nasal lining offers a non-oral, needle-free route, which can make the practical experience of treatment dramatically simpler for someone who does not want injections in the routine. That does not mean the spray should be treated as automatically equivalent to injectable glutathione. Route matters, and your provider decides whether this formulation makes sense for the reason you are considering treatment.
The science underneath the molecule stays the same: glutathione participates in neutralizing reactive molecules as part of ordinary cellular antioxidant chemistry. That mechanism does not establish outcomes for detoxification, aging, immunity, or energy.
Absorption is the central question. If you are looking beyond generic detox language, the nasal route deserves form-specific logic and practical expectations.
Read the evidence →For people who like the molecule more than the needle.
The Needle-Averse
You are interested in clinician-guided glutathione but know an injection routine is not one you are likely to keep. A nasal format makes the practical question easier.
The Mechanism-First Patient
You want the antioxidant biology without the cleanse narrative. Glutathione already has a legitimate endogenous role, which is enough to discuss without inflating it.
The Simplicity Seeker
You know adherence gets worse when a routine becomes a project. A nasal spray is a smaller daily ask, provided your clinician determines the route fits your case.
Compounded glutathione nasal spray is not an FDA-approved drug product. A licensed provider sets candidacy and cadence from your full intake, and results vary.
This might not be the right fit if:
- Active nasal or sinus infection, recent nasal surgery, or significant nasal polyps
- Known hypersensitivity to glutathione or any component of the formulation
- Asthma or reactive airway disease, given reports of bronchospasm with inhaled glutathione
- Pregnancy or breastfeeding, where safety data are insufficient
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Glutathione Nasal Spray, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Compounded glutathione delivered as a needle-free nasal spray
- Endogenous antioxidant biology described at mechanism level, not as a promised outcome
- Schedule set after clinician review
- Prepared by a licensed 503A pharmacy to your individual prescription
- Response and tolerability reviewed through ongoing care
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Longevity.
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
Tirzepatide + B12 Microdose
Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care. (Contains tirzepatide and vitamin B12.)
Metformin ER
Diabetes made it famous. Longevity made it interesting again.
FDA-approved generic metformin ER with decades of metabolic use and a serious place in the longevity conversation.
What the research shows
Intranasal glutathione was tolerated, with no substantial difference in adverse events.
The detail
In a randomized, double-blind trial, 30 people with Parkinson disease received intranasal placebo, 300 mg per day, or 600 mg per day of reduced glutathione in three divided daily doses for three months. There were no substantial differences between groups in the number of adverse events reported or observed, and all groups met the trial’s tolerability criteria.1
Every group improved, including placebo; neither glutathione dose beat placebo.
The detail
In a double-blind, placebo-controlled Phase IIb trial, 45 people with Hoehn and Yahr Stage 1 to 3 Parkinson disease received intranasal placebo, 100 mg, or 200 mg of reduced glutathione three times daily for three months. Every group improved, including placebo; the 200 mg group improved on the total Unified Parkinson Disease Rating Scale by 4.6 points over baseline; neither glutathione dose was superior to placebo; and one participant in the 200 mg group developed cardiomyopathy.2
A single intranasal dose raised brain glutathione above baseline for about an hour.
The detail
In 15 participants with mid-stage Parkinson disease, a single 200 mg intranasal dose of reduced glutathione raised brain glutathione measured by magnetic resonance spectroscopy above baseline. The increase was not detectable eight minutes after administration but was present at every later time point across approximately one hour of measurement.3
Intravenous glutathione was tolerated but did not change symptom scores versus placebo.
The detail
In a randomized, double-blind pilot trial, 21 people with Parkinson disease whose motor symptoms were not adequately controlled on their existing regimen received intravenous glutathione 1,400 mg or placebo three times weekly for four weeks. Glutathione was well tolerated, reported adverse events were similar in the two groups, and there were no significant differences in changes in Unified Parkinson Disease Rating Scale scores.4
A single oral dose did not raise plasma glutathione over 270 minutes.
The detail
In 7 healthy volunteers given a single oral dose of glutathione of 0.15 mmol per kilogram, approximately 3 grams, plasma glutathione, cysteine and glutamate did not increase significantly over the following 270 minutes, a result the investigators attributed to hydrolysis by intestinal and hepatic gamma-glutamyltransferase and interpreted as negligible systemic availability of oral glutathione.5
Oral glutathione raised levels 30 to 35 percent, and they returned to baseline after washout.
The detail
In a six-month randomized, double-blind, placebo-controlled trial, 54 non-smoking adults took oral glutathione at 250 mg or 1,000 mg per day. At six months the 1,000 mg group showed glutathione increases of 30 to 35 percent in erythrocytes, plasma and lymphocytes, and levels returned to baseline after a one-month washout.6
What it does not show
No glutathione product is FDA-approved for antioxidant support, healthy aging or detoxification.
The detail
No glutathione product is approved by the FDA for antioxidant support, healthy aging, detoxification or any of the other reasons people ask about it, and no intranasal glutathione product is FDA-approved for any indication.7
A compounded glutathione nasal spray is not an FDA-approved drug product.
The detail
A compounded glutathione nasal spray is not an FDA-approved drug product. It is prepared to an individual prescription by a licensed pharmacy, and the FDA states that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.8
Every intranasal trial was in Parkinson disease; none measured longevity, energy or immune function.
The intranasal evidence is small, short and narrow, and all of it came from one research group.
Neither intranasal dose separated from placebo, and a brain measurement is not a clinical outcome.
The detail
The one randomized trial designed to evaluate symptomatic relief did not separate either intranasal dose from placebo, no trial has compared intranasal glutathione against injectable or oral glutathione, and showing that an intranasal dose raises glutathione in brain tissue is a biochemical measurement rather than evidence of a clinical outcome.23
- Mischley LK, Leverenz JB, Lau RC, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione… Mov Disord. 2015.
- Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb study of intranasal glutathione in Parkinson's disease. J Parkinsons Dis. 2017.
- Mischley LK, Conley KE, Shankland EG, et al. Central nervous system uptake of intranasal glutathione in Parkinson's… NPJ Parkinsons Dis. 2016.
- Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione… Mov Disord. 2009.
- Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992.
- Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body… Eur J Nutr. 2015.
- Drugs@FDA, the FDA database of approved drug products, searched for glutathione as an active ingredient on 11 August 2026; the only approved applications are surgical irrigating solutions, and no nasal, injectable or oral glutathione drug product is approved.FDA
- Compounding and the FDA: Questions and Answers U.S Food and Drug…FDA
Do not use if you have
- Asthma and reactive airway disease are screened, alongside active sinus infection, recent nasal surgery and nasal polyps
Serious risks
- One participant on the higher dose in a three-month trial developed tachycardia and a newly diagnosed cardiomyopathy and withdrew
- Nebulized glutathione has been shown to narrow the airways in people with mild asthma, which is a different route from a spray
Commonly reported
- Sinus irritation and headache were the local complaints in the published trials of intranasal glutathione
- Adverse event rates did not separate from placebo
Because it is a nasal spray
- Glutathione has a mild sulfur smell, which is more noticeable with a nasal spray
The investigators could not establish whether the medicine was responsible, and recommended that future studies screen for cardiac effects. Human safety data for compounded intranasal glutathione is limited, which is the reason this sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
The clearest difference is practical: the spray avoids a needle. Route can also change how a medication is delivered and absorbed, so the two formats should not be treated as automatically interchangeable. Your provider decides which route fits your situation.
After provider approval, the pharmacy prepares the compounded spray for fulfillment. You can cancel your plan if your needs change, and your care team remains available for questions about the prescription.
Inhaled glutathione has been reported to trigger bronchospasm in people with asthma or reactive airways, so breathing conditions belong in your Assessment. Nasal irritation, stinging, or congestion can also occur. Your clinician weighs that history before prescribing.